TITLE

Valeant Will Try to Replace Cephalon Board Next Week

PUB. DATE
April 2011
SOURCE
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the efforts of Valeant Pharmaceuticals International Inc. to replace the Board of Directors of Cephalon Inc. with its nominees in the U.S. Valeant's chief executive officer (CEO) J. Michael Pearson stated that the company would appeal directly to the shareholders of Cephalon through consent solicitation. It also notes that the company had advised Valeant its work with financial advisors to review each proposal with the intentions of its directors to respond in due course.
ACCESSION #
60167019

 

Related Articles

  • Cephalon Rejects Valeant's Hostile $5.7B Takeover Bid.  // BioWorld Today;4/6/2011, Vol. 22 Issue 66, p1 

    This article reports on the rejection by Cephalon Inc. of an unsolicited takeover bid from Valeant Pharmaceuticals International Inc. According to Cephalon, the takeover bid is inadequate and not in the best interests of its shareholders. Particular focus is given to the increase in Cephalon's...

  • Valeant Puts its $5.7B Offer to Cephalon's Stockholders. Shaffer, Catherine // BioWorld Today;4/7/2011, Vol. 22 Issue 67, p1 

    The article reports on the moves of Valeant Pharmaceuticals International Inc. to replace the board of directors of Cephalon Inc. following a rejection of its takeover bid in March 2011. A consent solicitation has been filed with the Securities and Exchange Commission (SEC) to replace Cephalon's...

  • Valeant Will Try to Replace Cephalon Board Next Week. Wall, Tom // BioWorld Today;3/31/2011, Vol. 22 Issue 62, p1 

    This article reports on the attempt by Valeant Pharmaceuticals International Inc. to replace the board of directors of Cephalon Inc. Valeant Chief Executive Officer (CEO) J. Michael Pearson will appeal directly to shareholders of Cephalon about its plan to nominate members of the board. The...

  • Valeant Eyes Higher Offer For Cephalon.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p227 

    The article reports on the plan of Valeant Pharmaceuticals International Inc. to increase its 5.7 billion-dollar bid price to acquire Cephalon Inc. in 2011.

  • TOP STORIES.  // MondayMorning;4/11/2011, Vol. 18 Issue 14, p1 

    The article presents U.S. news briefs. U.S. House Republicans have proposed a plan to overhaul the federal budget and slash the deficit in coming years with a cut in spending and 25% cap on tax rates. Cephalon Inc. has rejected a hostile bid worth 5.7 billion dollars from Valeant Pharmaceuticals...

  • Teva Outbids Valeant for Cephalon in $6.8B Cash Offer. Shaffer, Catherine // BioWorld International;5/4/2011, Vol. 16 Issue 18, p1 

    The article reports on the acquisition of Cephalon Inc. by Teva Pharmaceutical Industries after beating a hostile bid from Valeant Pharmaceutical International Inc. As a result of this merger, Teva and Cephalon will boast a combined product lineup that focuses on neurology, respiratory care,...

  • Teva Outbids Valeant for Cephalon in $6.8B Cash Offer. Shaffer, Catherine // BioWorld Today;5/3/2011, Vol. 22 Issue 85, p1 

    The article reports that Israeli company Teva Pharmaceutical Industries Ltd. outbid Valeant Pharmaceutical International Inc. to acquire Cephalon Inc. Teva will purchase Cephalon for 6.8 billion dollars in cash, beating the hostile bid of 5.7 billion dollars placed by Valeant. Teva's purchase of...

  • Potential Cephalon Bid Won't Endanger $1.8B Mesoblast Deal. Moran, Nuala // BioWorld International;4/6/2011, Vol. 16 Issue 14, p1 

    This article reports on the move of Mesoblast Ltd. to reassure shareholders that it will not be affected by an offer of Valeant Pharmaceuticals International Inc. to acquire Mesoblast's partner, Cephalon Inc. According to Mesoblast, the offer will not affect its clinical studies with Cephalon....

  • Teva hits bull's eye with Cephalon. Carey, Karen // Nature Biotechnology;Jul2011, Vol. 29 Issue 7, p561 

    The article focuses on Petach Tikva's Teva that won the bid for Cephalon at 6.8 billion U.S. dollars against the bid of Valeant Pharmaceuticals of 5.7 billion U.S. dollars. It mentions the oncology, central nervous system and pain drug development projects of Cephalon including the phase 2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics